Our team brings together pioneers in probiotic formulation, metabolic biology, and translational research.
A pioneer of the world’s most clinically documented probiotic formulation and the scientific force behind Oxxyslab’s oxygen-modulating mechanism.
Prof. De Simone is a globally recognized authority in probiotic therapeutics and the original inventor of the De Simone Formulation—one of the world’s most clinically validated probiotic compositions. His formulation, formerly marketed as VSL#3®, is now commercialized as Visbiome® in the U.S. and Canada and as CDS22-formula®, De Simone®, and Visiopro® in Europe and other regions.
His technologies and discoveries provide the scientific foundation for Oxxyslab’s novel oxygen-modulating mechanism.
At ValeasO2, he guides scientific vision, research prioritization, and clinical translation.
A microbial technologist whose discoveries uncovered Oxxyslab’s oxygen-sparing pathways and mechanistic underpinnings.
Dr. Marazzato is a leading expert in food microbiology and applied microbial technologies. His work has been central to defining Oxxyslab’s mechanism of action—including oxygen-sparing effects, HIF-1α modulation, mitochondrial protection, and systemic oxygen redistribution.
He oversees ValeasO2’s mechanistic research programs, preclinical development, and global scientific collaborations.
An industry veteran who built and scaled global probiotic businesses and now leads Oxxyslab’s commercialization strategy.
Scott is an established leader in the probiotic therapeutics industry, previously launching and growing a global probiotic supplement business into the category leader during his tenure at DuPont (and its legacy organizations Danisco and Rhodia). His expertise spans commercialization, scientific messaging, market development, operations, and brand strategy across international markets.
At ValeasO2, Scott leads corporate strategy, partnerships, and the global rollout of Oxxyslab.
